PMID- 28049952
OWN - NLM
STAT- MEDLINE
DCOM- 20170203
LR  - 20221207
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 40
IP  - 1
DP  - 2017
TI  - Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in 
      Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced 
      Non-small Cell Lung Cancer.
PG  - 73-81
LID - 10.1248/bpb.b16-00623 [doi]
AB  - The purpose of this study was to propose a time-series modeling and simulation 
      (M&S) strategy for probabilistic cost-effective analysis in cancer chemotherapy 
      using a Monte-Carlo method based on data available from the literature. The 
      simulation included the cost for chemotherapy, for pharmaceutical care for 
      adverse events (AEs) and other medical costs. As an application example, we 
      describe the analysis for the comparison of four regimens, cisplatin plus 
      irinotecan, carboplatin plus paclitaxel, cisplatin plus gemcitabine (GP), and 
      cisplatin plus vinorelbine, for advanced non-small cell lung cancer. The factors, 
      drug efficacy explained by overall survival or time to treatment failure, 
      frequency and severity of AEs, utility value of AEs to determine QOL, the drugs' 
      and other medical costs in Japan, were included in the model. The simulation was 
      performed and quality adjusted life years (QALY) and incremental 
      cost-effectiveness ratios (ICER) were calculated. An index, percentage of 
      superiority (%SUP) which is the rate of the increased cost vs. QALY-gained plots 
      within the area of positive QALY-gained and also below some threshold values of 
      the ICER, was calculated as functions of threshold values of the ICER. An M&S 
      process was developed, and for the simulation example, the GP regimen was the 
      most cost-effective, in case of threshold values of the ICER=$70000/year, the 
      %SUP for the GP are more than 50%. We developed an M&S process for probabilistic 
      cost-effective analysis, this method would be useful for decision-making in 
      choosing a cancer chemotherapy regimen in terms of pharmacoeconomic.
FAU - Chisaki, Yugo
AU  - Chisaki Y
AD  - Education and Research Center for Clinical Pharmacy, Kyoto Pharmaceutical 
      University.
FAU - Nakamura, Nobuhiko
AU  - Nakamura N
FAU - Yano, Yoshitaka
AU  - Yano Y
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Antineoplastic Agents)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7673326042 (Irinotecan)
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
RN  - Q6C979R91Y (Vinorelbine)
RN  - XT3Z54Z28A (Camptothecin)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*economics/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse 
      effects/*economics/therapeutic use
MH  - Camptothecin/adverse effects/analogs & derivatives/economics/therapeutic use
MH  - Carboplatin/adverse effects/economics/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/*economics
MH  - Cisplatin/adverse effects/economics/therapeutic use
MH  - Computer Simulation
MH  - *Cost-Benefit Analysis
MH  - Deoxycytidine/adverse effects/analogs & derivatives/economics/therapeutic use
MH  - Humans
MH  - Irinotecan
MH  - Lung Neoplasms/drug therapy/*economics
MH  - *Models, Economic
MH  - Paclitaxel/adverse effects/economics/therapeutic use
MH  - Quality-Adjusted Life Years
MH  - Vinblastine/adverse effects/analogs & derivatives/economics/therapeutic use
MH  - Vinorelbine
MH  - Gemcitabine
EDAT- 2017/01/05 06:00
MHDA- 2017/02/06 06:00
CRDT- 2017/01/05 06:00
PHST- 2017/01/05 06:00 [entrez]
PHST- 2017/01/05 06:00 [pubmed]
PHST- 2017/02/06 06:00 [medline]
AID - 10.1248/bpb.b16-00623 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2017;40(1):73-81. doi: 10.1248/bpb.b16-00623.